# HS research update (2026-11-15): What’s new on PubMed?

Canonical URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-11-15/
Markdown URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-11-15.md
Plain text URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-11-15.txt
Language: en
Category: Research
Published: 2026-11-15
Last updated: 2026-11-15
Last editorially reviewed: 2026-11-15
Next scheduled review: 2027-11-15

Author: Dr. rer. nat. Dennis Alexander Kwiatkowski (Biochemist, Scientific Writer and Pharma Expert)
Scientific editor: Dr. rer. nat. Dennis Alexander Kwiatkowski
Reviewer qualifications: Biochemist, Scientific Writer and Pharma Expert
Review scope: Scientific literature, clinical guidelines, sources, and editorial clarity
Clinical reviewer: No independent clinical review
Tags: Acne Inversa, Hidradenitis Suppurativa, HS, Research, hidradenitis suppurativa, acne inversa, research update, biologics, comorbidities, diagnostic delay, jak inhibitor, pain, quality of life, surgery, wound care

> A patient-friendly overview of new PubMed publications on hidradenitis suppurativa (acne inversa) — with sources, clear limitations, and no medical advice.

Medical disclaimer: This website is for general educational information only and does not replace medical advice, diagnosis, or treatment. Please speak with qualified medical professionals about symptoms or treatment decisions.

## Article

## Publication overview

This update includes **18 PubMed publications with abstracts** from the monitoring window **2026-11-01 to 2026-11-15**. The most common themes are **biologics, surgery, pain, comorbidities, quality of life**.

- Compared with the previous update: not automatically assessed.
- No guideline/NEJM/Lancet-style high-impact matches with abstracts in this window.
- This is a research overview, not a guideline update or medical recommendation.

## Top highlights

The most useful signal this round is not a single treatment instruction. It is what researchers are looking at more closely: wound healing after procedures, possible new anti-inflammatory approaches, care quality, and comorbidities.

- **Combination therapies for hidradenitis suppurativa: Narrative review of current strategies and emerging perspectives.:** The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa (HS) is a chronic, recurrent, and debilitating inflammatory dermatosis affecting approximately 1% of the population, with a female predominance and substantial psychosocial burden. Clinically,… What makes it notable here is that it approaches HS through **diagnostic delay, jak inhibitor, wound care, surgery, biologics, pain, comorbidities**. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. ([PMID 43034520](https://pubmed.ncbi.nlm.nih.gov/43034520/))
- **Patient Journey, HS Burden and Unmet Need across Denmark and Norway: Real-World Data from the HISREG Registry.:** The abstract describes a new publication. In practical terms, it focuses on this question or finding: Patients with hidradenitis suppurativa experience considerable disease burden and reduced health-related quality of life (HRQoL). Diagnostic delays are common and may impede timely treatment initiation, contributing t… What makes it notable here is that it approaches HS through **diagnostic delay, pain, quality of life, surgery**. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. ([PMID 42980589](https://pubmed.ncbi.nlm.nih.gov/42980589/))
- **Surgical Management of Hidradenitis Suppurativa: Current Evidence and Practical Guidance.:** The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa is a chronic inflammatory skin disease that frequently progresses from recurrent nodules and abscesses to tunnels, fibrosis, scarring, and substantial quality-of-life impairment. Medical thera… What makes it notable here is that it approaches HS through **biologics, wound care, comorbidities, surgery**. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. ([PMID 42989463](https://pubmed.ncbi.nlm.nih.gov/42989463/))
- **Longitudinal cohort study of immune-mediated inflammatory diseases within the systems medicine framework of the DREAM Centre: a study protocol.:** The abstract describes a new publication. In practical terms, it focuses on this question or finding: Immune-mediated inflammatory diseases (IMIDs) are chronic disorders characterised by dysregulated immune responses affecting multiple organ systems, including the skin, joints and gastrointestinal (GI) tract. Progress… What makes it notable here is that it approaches HS through **comorbidities, biologics, quality of life**. The main limitation to keep in mind is: As an observational analysis, it can describe associations but cannot securely prove cause and effect. ([PMID 43015015](https://pubmed.ncbi.nlm.nih.gov/43015015/))
- **Comparative effectiveness of IL-12/23 and IL-23 inhibitors versus JAK inhibitors in patients with inflammatory bowel disease and hidradenitis suppurativa: a real-world propensity-matched analysis.:** The abstract describes a new publication. In practical terms, it focuses on this question or finding: Inflammatory bowel disease (IBD) and hidradenitis suppurativa (HS) frequently coexist and share overlapping immune pathways, yet comparative real-world outcomes between IL-12/23 or IL-23 inhibitors and Janus kinase (J… What makes it notable here is that it approaches HS through **biologics, comorbidities, jak inhibitor**. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. ([PMID 42991151](https://pubmed.ncbi.nlm.nih.gov/42991151/))

## Featured publication

The featured paper is **Combination therapies for hidradenitis suppurativa: Narrative review of current strategies and emerging perspectives.** in **Sage open chronic disease** ([PMID 43034520](https://pubmed.ncbi.nlm.nih.gov/43034520/)). The abstract mainly says this: Hidradenitis suppurativa (HS) is a chronic, recurrent, and debilitating inflammatory dermatosis affecting approximately 1% of the population, with a female predominance and substantial psychosocial burden. Clinically,…

Why it stands out: it connects to the priority themes **diagnostic delay, jak inhibitor, wound care, surgery, biologics, pain, comorbidities** and shows what HS researchers are trying to clarify right now. For readers, it matters because it gives one concrete example of how the field is framing a practical question or possible mechanism. The main limitation is that From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full.

## What this may mean for patients (carefully, no advice)

If you live with HS, research updates can help you make sense of what’s being studied — for example which outcomes (pain, quality of life) researchers measure, or which comorbidities are increasingly part of the conversation.

But even when a study sounds promising, it usually does not tell you what is right **for you personally**. Consider using new findings as questions for your next appointment (e.g., “What are realistic goals for me?” or “Which related conditions should we keep an eye on?”), not as instructions.

## What we don’t know / limitations

- This update includes **only** PubMed items with an abstract (without an abstract, safe summarization is limited).
- Studies vary widely (design, populations, outcome measures).
- This update provides **no** treatment advice and cannot assess individual risk.

## Important: decisions belong in clinician conversations

This article is an editorial overview and is **not medically reviewed**. If something here worries or interests you, use it as a conversation starter for your next appointment. Decisions should always be made with qualified healthcare professionals.

## FAQ

### Why are there only a few new publications here?
This format is deliberately strict: it includes only new PubMed items from the monitoring window that have an abstract and were not already covered in earlier posts.

### Does a new paper mean my treatment should change?
No. A single publication can be useful to know about, but it is usually not enough to guide decisions for one specific person.

### Why emphasize limitations so much?
Because abstracts show only part of the picture. Study design, patient population, endpoints, and follow-up all matter before results can be interpreted responsibly.

## Sources & original papers

Each point below maps to an original source (PubMed link, plus DOI/PMCID when available).

## References

1. Evaluation of the Flap Reconstruction of Areas Affected by Hidradenitis Suppurativa. - Plastic and reconstructive surgery. Global open, 2026 — PMID 43032865 · DOI 10.1097/GOX.0000000000008272 · PMCID PMC13766592 - https://pubmed.ncbi.nlm.nih.gov/43032865/
2. [Complex reconstruction of severe buried penis after multiple genital surgeries for hidradenitis suppurativa and cystic lymphangioma: A case report]. - Annales de chirurgie plastique et esthetique, 2026 — PMID 43020705 · DOI 10.1016/j.anplas.2026.04.001 - https://pubmed.ncbi.nlm.nih.gov/43020705/
3. Regenerative Medicine in Chronic Inflammatory Dermatoses: A Scoping Review. - Cureus, 2026 — PMID 43017419 · DOI 10.7759/cureus.119462 · PMCID PMC13754400 - https://pubmed.ncbi.nlm.nih.gov/43017419/
4. Longitudinal cohort study of immune-mediated inflammatory diseases within the systems medicine framework of the DREAM Centre: a study protocol. - BMJ open, 2026 — PMID 43015015 · DOI 10.1136/bmjopen-2026-121246 · PMCID PMC13756429 - https://pubmed.ncbi.nlm.nih.gov/43015015/
5. Cutaneous presentations of digestive tract disorders and liver diseases. - Dermatologie (Heidelberg, Germany), 2026 — PMID 43009610 · DOI 10.1007/s00105-026-05802-2 - https://pubmed.ncbi.nlm.nih.gov/43009610/
6. Hidradenitis Suppurativa in Transgender and Gender Diverse Populations: Bridging Gaps in Care and Knowledge. - American journal of clinical dermatology, 2026 — PMID 43007642 · DOI 10.1007/s40257-026-01093-4 - https://pubmed.ncbi.nlm.nih.gov/43007642/
7. Surgical Management of Hidradenitis Suppurativa: Current Evidence and Practical Guidance. - Journal of cutaneous medicine and surgery, 2026 — PMID 42989463 · DOI 10.1177/12034754261501145 - https://pubmed.ncbi.nlm.nih.gov/42989463/
8. End-of-Dose Effect as a Guide for Biologic Optimization in Hidradenitis Suppurativa. - JAMA dermatology, 2026 — PMID 42981090 · DOI 10.1001/jamadermatol.2026.4435 · PMCID PMC13735192 - https://pubmed.ncbi.nlm.nih.gov/42981090/
9. Patient Journey, HS Burden and Unmet Need across Denmark and Norway: Real-World Data from the HISREG Registry. - Acta dermato-venereologica, 2026 — PMID 42980589 · DOI 10.2340/actadv.v106.adv-2026-0505 · PMCID PMC13733279 - https://pubmed.ncbi.nlm.nih.gov/42980589/
10. Emotional and social burden of hidradenitis suppurativa: a qualitative multi-centre narrative medicine project in Italy. - BMJ open, 2026 — PMID 42971608 · DOI 10.1136/bmjopen-2025-111830 · PMCID PMC13735344 - https://pubmed.ncbi.nlm.nih.gov/42971608/
11. Xianfang Huoming Decoction ameliorates hidradenitis suppurativa-like pathology by restoring NCSTN/Notch signaling homeostasis in Ncstn - Journal of molecular histology, 2026 — PMID 42970123 · DOI 10.1007/s10735-026-10990-1 - https://pubmed.ncbi.nlm.nih.gov/42970123/
12. Remibrutinib (Rhapsido - Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026 — PMID 42970053 · DOI 10.1007/s00044-026-03634-2 - https://pubmed.ncbi.nlm.nih.gov/42970053/
13. Obesity-associated transcriptomic remodelling in hidradenitis suppurativa and treatment response. - Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 — PMID 42969400 · DOI 10.1111/jdv.70829 - https://pubmed.ncbi.nlm.nih.gov/42969400/
14. A Rare Case of Coexistent Hidradenitis Suppurativa, Steatocystoma Multiplex with Dorsal Aquagenic Keratoderma: The Elephant in the Room Regarding a 'Follicular Occlusion Pentad'. - Indian journal of dermatology, 2026 — PMID 43011598 · DOI 10.4103/ijd.ijd_185_25 · PMCID PMC13750737 - https://pubmed.ncbi.nlm.nih.gov/43011598/
15. Comparative effectiveness of IL-12/23 and IL-23 inhibitors versus JAK inhibitors in patients with inflammatory bowel disease and hidradenitis suppurativa: a real-world propensity-matched analysis. - Crohn's & colitis 360, 2026 — PMID 42991151 · DOI 10.1093/crocol/otag086 · PMCID PMC13735508 - https://pubmed.ncbi.nlm.nih.gov/42991151/
16. Circulating NET-associated parameters across chronic inflammatory skin diseases: a comparative study. - Frontiers in medicine, 2026 — PMID 42996497 · DOI 10.3389/fmed.2026.1918335 · PMCID PMC13739568 - https://pubmed.ncbi.nlm.nih.gov/42996497/
17. Hidradenitis suppurativa in primary care: From early recognition to modern management. - South African family practice : official journal of the South African Academy of Family Practice/Primary Care, 2026 — PMID 43000727 · DOI 10.4102/safp.v68i1.6318 · PMCID PMC13636393 - https://pubmed.ncbi.nlm.nih.gov/43000727/
18. Combination therapies for hidradenitis suppurativa: Narrative review of current strategies and emerging perspectives. - Sage open chronic disease, 2026 — PMID 43034520 · DOI 10.1177/27558428261449178 · PMCID PMC13768674 - https://pubmed.ncbi.nlm.nih.gov/43034520/
